NASDAQ:BLPH

Bellerophon Therapeutics Stock Forecast, Price & News

$3.96
-0.01 (-0.25 %)
(As of 09/21/2021 04:00 PM ET)
Add
Compare
Today's Range
$3.93
$4.02
50-Day Range
$3.75
$4.50
52-Week Range
$3.66
$10.43
Volume12,246 shs
Average Volume105,483 shs
Market Capitalization$37.64 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.53
30 days | 90 days | 365 days | Advanced Chart
Receive BLPH News and Ratings via Email

Sign-up to receive the latest news and ratings for Bellerophon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Bellerophon Therapeutics logo

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc. focuses on developing products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. Its product pipeline include PH-ILD, PH-COPD and PH-Sarc. The company was founded in 2009 and is headquartered in Warren, NJ.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.14 out of 5 stars

Medical Sector

413th out of 1,352 stocks

Pharmaceutical Preparations Industry

202nd out of 665 stocks

Analyst Opinion: 3.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Bellerophon Therapeutics (NASDAQ:BLPH) Frequently Asked Questions

Is Bellerophon Therapeutics a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bellerophon Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Bellerophon Therapeutics stock.
View analyst ratings for Bellerophon Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Bellerophon Therapeutics?

Wall Street analysts have given Bellerophon Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Bellerophon Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Bellerophon Therapeutics?

Bellerophon Therapeutics saw a drop in short interest in the month of August. As of August 13th, there was short interest totaling 82,500 shares, a drop of 16.9% from the July 29th total of 99,300 shares. Based on an average daily trading volume, of 174,300 shares, the days-to-cover ratio is currently 0.5 days. Currently, 1.0% of the shares of the company are sold short.
View Bellerophon Therapeutics' Short Interest
.

When is Bellerophon Therapeutics' next earnings date?

Bellerophon Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Bellerophon Therapeutics
.

How were Bellerophon Therapeutics' earnings last quarter?

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) posted its quarterly earnings results on Thursday, August, 5th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.26.
View Bellerophon Therapeutics' earnings history
.

How has Bellerophon Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Bellerophon Therapeutics' stock was trading at $6.29 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BLPH stock has decreased by 37.0% and is now trading at $3.96.
View which stocks have been most impacted by COVID-19
.

When did Bellerophon Therapeutics' stock split? How did Bellerophon Therapeutics' stock split work?

Shares of Bellerophon Therapeutics reverse split on Monday, February 10th 2020. The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 7th 2020. An investor that had 100 shares of Bellerophon Therapeutics stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for BLPH?

2 Wall Street analysts have issued 12 month price objectives for Bellerophon Therapeutics' stock. Their forecasts range from $22.00 to $22.00. On average, they anticipate Bellerophon Therapeutics' share price to reach $22.00 in the next year. This suggests a possible upside of 455.6% from the stock's current price.
View analysts' price targets for Bellerophon Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Bellerophon Therapeutics' key executives?

Bellerophon Therapeutics' management team includes the following people:
  • Fabian Tenenbaum, Chief Executive Officer & Director
  • Parag Suresh Shah, Vice President-Business Operations
  • Assaf Korner, Chief Financial Officer & Secretary
  • Amy Edmonds, VP-Clinical Operations & Administration
  • Edwin L. Parsley, Chief Medical Officer

Who are some of Bellerophon Therapeutics' key competitors?

What other stocks do shareholders of Bellerophon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellerophon Therapeutics investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Corbus Pharmaceuticals (CRBP), Novavax (NVAX), Pfizer (PFE), Verastem (VSTM), Gilead Sciences (GILD), OPKO Health (OPK), SCYNEXIS (SCYX) and Dynavax Technologies (DVAX).

When did Bellerophon Therapeutics IPO?

(BLPH) raised $60 million in an initial public offering (IPO) on Friday, February 13th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Leerink Partners and Cowen and Company served as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.

What is Bellerophon Therapeutics' stock symbol?

Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH."

Who are Bellerophon Therapeutics' major shareholders?

Bellerophon Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.54%), Renaissance Technologies LLC (2.70%), Telemetry Investments L.L.C. (0.96%), Geode Capital Management LLC (0.61%), Northern Trust Corp (0.38%) and State Street Corp (0.22%). Company insiders that own Bellerophon Therapeutics stock include Associates Iv L P Venrock, New Mountain Investments Ii, L, Theodore T Wang and Wassim Fares.
View institutional ownership trends for Bellerophon Therapeutics
.

Which major investors are selling Bellerophon Therapeutics stock?

BLPH stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp, State Street Corp, Vanguard Group Inc., and Geode Capital Management LLC.
View insider buying and selling activity for Bellerophon Therapeutics
or view top insider-selling stocks.

Which major investors are buying Bellerophon Therapeutics stock?

BLPH stock was purchased by a variety of institutional investors in the last quarter, including Telemetry Investments L.L.C., Renaissance Technologies LLC, Virtu Financial LLC, Ergoteles LLC, Millennium Management LLC, and JPMorgan Chase & Co.. Company insiders that have bought Bellerophon Therapeutics stock in the last two years include Theodore T Wang, and Wassim Fares.
View insider buying and selling activity for Bellerophon Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Bellerophon Therapeutics?

Shares of BLPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bellerophon Therapeutics' stock price today?

One share of BLPH stock can currently be purchased for approximately $3.96.

How much money does Bellerophon Therapeutics make?

Bellerophon Therapeutics has a market capitalization of $37.64 million. The biotechnology company earns $-24,730,000.00 in net income (profit) each year or ($3.06) on an earnings per share basis.

How many employees does Bellerophon Therapeutics have?

Bellerophon Therapeutics employs 21 workers across the globe.

What is Bellerophon Therapeutics' official website?

The official website for Bellerophon Therapeutics is www.bellerophon.com.

Where are Bellerophon Therapeutics' headquarters?

Bellerophon Therapeutics is headquartered at 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059.

How can I contact Bellerophon Therapeutics?

Bellerophon Therapeutics' mailing address is 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059. The biotechnology company can be reached via phone at (908) 574-4770 or via email at [email protected].


This page was last updated on 9/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.